ARWR Arrowhead Pharmaceuticals Inc

Item 7.01 Regulation FD Disclosure

On December 16, 2021, Arrowhead Madison, Inc. (“Arrowhead Madison”), a subsidiary of Arrowhead Pharmaceuticals, Inc., closed on its acquisition of 13.06 acres of land in Verona, Wisconsin (the “Verona Land”) for a purchase price of $2.986 million. Arrowhead Madison intends to use the Verona Land to construct a manufacturing facility and related process development and analytical laboratories. At closing, Arrowhead Madison also entered into an Option to Purchase agreement with the land seller, Anorev East LLC, granting Arrowhead Madison an exclusive seven (7) year option to purchase an additional parcel of approximately 6.24 acres which abuts the Verona Land for a purchase price of $5.25 to $6.57 per square foot, depending on the date upon which Arrowhead Madison exercises the option and closes on the purchase of such additional parcel. On December 20, 2021, we issued a press release in connection with the transaction, which is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.